Deans' stroke musings: Strategy for Improving Stroke Treatment Response

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, August 25, 2025

Strategy for Improving Stroke Treatment Response

NOTHING ON CREATING A STROKE STRAEGY TO SOLVE STROKE TO 100% RECOVERY! Bad title!

Strategy for Improving Stroke Treatment Response

ClinicalTrials.gov IDNCT05948566

SponsorTranslational Sciences, Inc.

Information Provided byEva Mistry, MBBS

Study Start (Actual)2024-03-18

Primary Completion (Estimated) 2027-07

Study Completion (Estimated)2027-12

Enrollment (Estimated)300

Study TypeInterventional

Last Update Posted 2025-08-19

Study Overview

Brief Summary

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

To learn more, visitClinicalTrials.gov